USE OF THERAPEUTIC AMFETAMINES IN PREGNANCY
Date of issue: June 2026, Version: 2.0
Therapeutic amfetamines (amphetamines), including lisdexamfetamine and dexamfetamine (dexamphetamine), are licensed to treat attention deficit hyperactivity disorder (ADHD). Dexamfetamine is also licensed to treat narcolepsy.
Untreated ADHD can increase the likelihood of risk-taking behaviour, including smoking and alcohol or recreational drug use. In addition, ADHD often manifests with anxiety-type behaviours in females; therefore, the continued treatment of ADHD in pregnancy may be beneficial for some women. An individualised discussion of the risks and benefits of continued treatment is recommended.
Thirteen studies describe over 22,400 unique therapeutic amfetamine-exposed pregnancies. Where details were provided, only three studies analysed outcomes specifically following exposure after the first trimester.
The available safety data have not associated use of therapeutic amfetamines in early pregnancy with an increased risk of congenital major malformation overall, or with any specific cardiac malformation. Evidence regarding other pregnancy outcomes is conflicting and likely highly confounded by the maternal indication for treatment and/or other associated concurrent risk factors. Possible increased risks of stillbirth, miscarriage, preterm delivery, low infant birth weight, placental abruption, and pre-eclampsia have been reported. These findings require confirmation but may be biologically plausible given the vasoconstrictive effects of amfetamines.
Therapeutic amfetamines are centrally acting stimulants and use around the time of delivery may therefore pose a risk of neonatal withdrawal and associated complications. Lower Apgar scores, and the requirement for neonatal resuscitation and neonatal admission have been described following in utero exposure. Pregnancies with exposure to CNS-acting medication in the later stages should ideally be delivered in a unit with facilities to monitor for and manage neonatal complications.
Two studies of over 5,000 exposed pregnancies do not provide compelling evidence that gestational exposure to amfetamines increases the risk of autism spectrum disorder (ASD) or ADHD.
Exposure to therapeutic amfetamines at any stage in pregnancy would not usually be regarded as medical grounds for termination of pregnancy. Given the current evidence base, additional fetal monitoring, particularly of fetal growth, may be warranted on a case-by-case basis. Other risk factors may be present in individual cases which could independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of considering such factors when performing case-specific risk assessments.
This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.
If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.
If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.